Estados Unidos · Plataformas y datos · MarketBeat

Moderna Melanoma Therapy Cuts Recurrence Risk 42% in Phase 3 Trial

Publicado por MarketBeat · Estados Unidos hace 1 h

Moderna (NASDAQ:MRNA) presented Phase 3 results for intismeran, its individualized neoantigen therapy, in combination with Merck’s pembrolizumab for patients with resected…

Leer el artículo completo en MarketBeat Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.marketbeat.com)

Moderna Melanoma Therapy Cuts Recurrence Risk 42% in Phase 3 Trial

También te puede interesar

Is Berkshire Bending the Rules With Bending Spoons?

Musk says Ukraine violated Starlink terms with offensive drone strikes

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

Lula, Bolsonaro rally supporters on final day before Brazil presidential runoff

First Interstate BancSystem: 3 Key Takeaways for Long-Term Investors

Bank of America resets Tesla forecast as Robotaxi miles double

Moderna Melanoma Therapy Cuts Recurrence Risk 42% in Phase 3 Trial

Compartir

También te puede interesar

Is Berkshire Bending the Rules With Bending Spoons?

Musk says Ukraine violated Starlink terms with offensive drone strikes

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

Lula, Bolsonaro rally supporters on final day before Brazil presidential runoff

First Interstate BancSystem: 3 Key Takeaways for Long-Term Investors

Bank of America resets Tesla forecast as Robotaxi miles double